Stockscreener 앱 받기
71.93
0.75%
-0.54
시간 외 거래:
72.28
0.35
+0.49%
전일 마감가:
$72.47
열려 있는:
$72.87
하루 거래량:
950.11K
Relative Volume:
0.51
시가총액:
$13.86B
수익:
$4.08B
순이익/손실:
$32.48M
주가수익비율:
513.79
EPS:
0.14
순현금흐름:
$16.80M
1주 성능:
+1.97%
1개월 성능:
+3.65%
6개월 성능:
+10.15%
1년 성능:
+17.00%
1일 변동 폭
$71.85
$73.00
1주일 범위
$69.65
$73.83
52주 변동 폭
$50.35
$83.95
인사이트 코퍼레이션 Stock (INCY) Company Profile
명칭
Incyte Corp
전화
(302) 498-6700
주소
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
INCY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
71.93 | 13.86B | 4.08B | 32.48M | 16.80M | 0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
인사이트 코퍼레이션 Stock (INCY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-17 | 개시 | UBS | Neutral |
| 2024-10-29 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-10-01 | 개시 | Wolfe Research | Outperform |
| 2024-09-18 | 다운그레이드 | Truist | Buy → Hold |
| 2024-07-02 | 다운그레이드 | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | 개시 | Deutsche Bank | Hold |
| 2024-04-23 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-02-23 | 개시 | Jefferies | Buy |
| 2024-02-14 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-11-21 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-07-25 | 개시 | Citigroup | Buy |
| 2023-05-04 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-04-10 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | 업그레이드 | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | 개시 | Piper Sandler | Overweight |
| 2022-08-03 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-08-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-07-28 | 개시 | Wells Fargo | Equal Weight |
| 2022-02-09 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-07-20 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-02-10 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | 개시 | Truist | Buy |
| 2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-06-16 | 개시 | The Benchmark Company | Hold |
| 2020-05-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-04-29 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | 재개 | William Blair | Outperform |
| 2020-03-13 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | 재개 | BofA/Merrill | Neutral |
| 2020-01-03 | 재확인 | BMO Capital Markets | Market Perform |
| 2020-01-03 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-10-03 | 개시 | Mizuho | Buy |
| 2019-09-12 | 개시 | BMO Capital Markets | Market Perform |
| 2019-09-05 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | 재개 | Morgan Stanley | Equal-Weight |
| 2019-09-05 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-05-21 | 개시 | Credit Suisse | Neutral |
| 2019-05-03 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2019-04-11 | 개시 | Stifel | Hold |
| 2019-04-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | 업그레이드 | William Blair | Mkt Perform → Outperform |
모두보기
인사이트 코퍼레이션 주식(INCY)의 최신 뉴스
Incyte Gains 15.3% In A Year: Is There Room For Further Growth? - Barchart
Short Interest in Incyte Co. (NASDAQ:INCY) Decreases By 13.1% - MarketBeat
INCY (Incyte) GF Value Rank : 8 (As of Jan. 20, 2025) - GuruFocus.com
Hennion & Walsh Asset Management Inc. Purchases 11,120 Shares of Incyte Co. (NASDAQ:INCY) - MarketBeat
What You Need To Know Ahead Of Incyte's Earnings Release - Barchart
Fed. Circ. Urged To Keep Block Of Sun Pharma Alopecia Drug - Law360
Contravisory Investment Management Inc. Has $750,000 Stock Holdings in Incyte Co. (NASDAQ:INCY) - MarketBeat
CHURCHILL MANAGEMENT Corp Has $12.36 Million Stock Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
Claro Advisors LLC Takes Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
JP Morgan 2025: Incyte expects period of ‘defining catalysts’ - Yahoo Finance
Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines - Yahoo Finance
Warm Autoimmune hemolytic anemia (WAIHA) Market Poised for Significant Growth from 2024 to 2034, Reports DelveInsight | Rigel Pharma, Incyte Crp., Sanofi, Johnson & Johnson, Janssen R&D - Barchart
Incyte's SWOT analysis: navigating patent cliff with promising pipeline - Investing.com
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
DPP-led Effort For Incyte Leads To Deal Of The Year Honors - Town Square Delaware LIVE
Incyte's (INCY) "Market Perform" Rating Reiterated at JMP Securities - MarketBeat
Incyte At JPM25: Eyes Transformational 2025 With Multiple Drug Launches And Expanding Pipeline - Benzinga
Warm Autoimmune hemolytic anemia (WAIHA) Market Poised - openPR
Pallas Capital Advisors LLC Makes New $1.01 Million Investment in Incyte Co. (NASDAQ:INCY) - MarketBeat
Has Incyte (INCY) Outpaced Other Medical Stocks This Year? - MSN
Anal Cancer Market on Track for Major Expansion by 2034, - openPR
Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference - Yahoo Finance
Analysts Set Incyte Co. (NASDAQ:INCY) Target Price at $76.29 - MarketBeat
Incyte: Multiple Drug Launches Bode Well For Future Growth - Seeking Alpha
Incyte (NASDAQ:INCY) Given "Neutral" Rating at Cantor Fitzgerald - MarketBeat
Incyte Corporation (INCY) Announces Executive Leadership Change - GuruFocus.com
Incyte Announces Retirement of Executive VP Barry Flannelly - TipRanks
JPMorgan Chase & Co. Reduces Holdings in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 8, 2025 - BioSpace
Incyte (MEX:INCY) Earnings Yield % : 0.09% (As of Jan. 08, 2025) - GuruFocus.com
Incyte Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
Follicular Lymphoma Market Expected to rise, 2034 | Epizyme|Eisai, Bayer Healthcare Pharmaceuticals, Verastem Oncology, Gilead Sciences, TG Therapeutics, Bristol-Myers-Squibb, Roche, Incyte Corp - The Globe and Mail
Follicular Lymphoma Market Expected to rise, 2034 | - openPR
CWA Asset Management Group LLC Acquires Shares of 27,984 Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte Corp. stock rises Friday, still underperforms market - MarketWatch
Centre Asset Management LLC Has $9.40 Million Stock Holdings in Incyte Co. (NASDAQ:INCY) - MarketBeat
CDK2/cyclin E1 inhibitors disclosed in Incyte patent - BioWorld Online
Incyte Corp. stock underperforms Monday when compared to competitors - MarketWatch
Principal Financial Group Inc. Has $14.59 Million Holdings in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte Corp. stock rises Tuesday, still underperforms market - MarketWatch
Is Incyte Stock Outperforming The Dow? - Barchart
Is Incyte Stock Outperforming the Dow? - Inkl
Franklin Resources Inc. Sells 50,188 Shares of Incyte Co. (NASDAQ:INCY) - MarketBeat
Sanctuary Advisors LLC Has $1.51 Million Stake in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte price target raised to $70 from $68 at Wells Fargo - Yahoo Finance
Incyte Corp. stock underperforms Thursday when compared to competitors - MarketWatch
The Analyst Verdict: Incyte In The Eyes Of 15 Experts - Benzinga
Wells Fargo & Company Issues Positive Forecast for Incyte (NASDAQ:INCY) Stock Price - MarketBeat
Analysts Set Incyte Co. (NASDAQ:INCY) Target Price at $76.18 - MarketBeat
Incyte corp principal accounting officer Tray Thomas sells $90,967 in stock - Investing.com India
Incyte Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
인사이트 코퍼레이션 (INCY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.62%
0.65%
자본화:
|
볼륨(24시간):